| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918099 | Radiotherapy and Oncology | 2015 | 6 Pages |
Abstract
This study suggests that MMC1 is efficacious and may be an alternative to MMC2 in patients with anal cancer treated with definitive chemoradiation, with the potential for less acute treatment-related toxicity. Randomized trials comparing these two regimens could be considered.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Evan C. White, Kelly Goldman, Alexey Aleshin, Winston W. Lien, Aroor R. Rao,